Zabedosertib

Zabedosertib (BAY 1834845) is a selective, orally active IRAK4 inhibitor with immunomodulatory potential, IC50 is 3.55 nM. IRAK4 is a protein kinase involved in signaling innate immune responses from Toll-like receptors[1]. Zabedosertib exhibits anti-inflammatory property against IL-β, LPS (HY-D1056) and Imiquimod (HY-B1080) induced inflammation[2].

Product Specifications

CAS Number

[1931994-81-8]

Product Name Alternative

BAY 1834845

UNSPSC

12352005

Target

IRAK

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/zabedosertib.html

Concentration

10mM

Purity

98.14

Solubility

DMSO : 125 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(C1=CC=CC(C(F)(F)F)=N1)NC2=CC3=CN(CCS(=O)(C)=O)N=C3C=C2C(C)(C)O

Molecular Formula

C20H21F3N4O4S

Molecular Weight

470.47

References & Citations

[1]Bothe, Ulrich; Siebenreicher, Holger; Schmidt, Nicole; Nubbemeyer, Reinhard; Boemer, Ulf; Guenther, Judith; Steuber, Holger; Lange, Martin; Stegmann, Christian; Sutter, Andreas; et al.New substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs.WO2016083433A1|[2]Li Q, et al., Oral IRAK4 inhibitor BAY-1834845 prevents acute respiratory distress syndrome. Biomed Pharmacother. 2022 Sep;153:113459.|[3]Bothe U, et al., Discovery of IRAK4 Inhibitors BAY1834845 (Zabedosertib) and BAY1830839. J Med Chem. 2024 Jan 25;67 (2) :1225-1242.